Associated Papers
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
36044908 (PubMed )
Supplement: gg23-giannikou_suptable1.xlsx › NF1
Detection of genomic alterations in breast cancer with circulating tumour DNA sequencing.
Kleftogiannis D et al.
Scientific Reports, 2020
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Zhang G et al.
Annals of Translational Medicine, 2019
TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia.
Wegert J et al.
The Journal of Pathology. Clinical Research, 2017
Development and clinical application of an integrative genomic approach to personalized cancer therapy.
Uzilov AV et al.
Genome Medicine, 2016
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations.
Kiel C et al.
Molecular Systems Biology, 2014
24803665 (PubMed )
Supplement: MSB-10-5-727-s13.xls › energies
Proteome-wide analysis of amino acid variations that influence protein lysine acetylation.
Suo SB et al.
Journal of Proteome Research, 2013
23298314 (PubMed )
Supplement: pr301007j_si_005.pdf
Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.
Nyström AM et al.
Clinical Genetics, 2009
Genome-wide analysis to predict protein sequence variations that change phosphorylation sites or their corresponding kinases.
Ryu GM et al.
Nucleic Acids Research, 2009
19139070 (PubMed )
Supplement: gkn1008_nar-01723-s-2008-File009.xls › TypeII_
NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome.
De Luca A et al.
American Journal of Human Genetics, 2005
Select a paper to view details